Identification
NameN6-(2,5-Dimethoxy-Benzyl)-N6-Methyl-Pyrido[2,3-D]Pyrimidine-2,4,6-Triamine
Accession NumberDB02583  (EXPT02658)
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS number175354-76-4
WeightAverage: 340.3797
Monoisotopic: 340.164773914
Chemical FormulaC17H20N6O2
InChI KeyHZTFNSCZLJLPEO-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N6O2/c1-23(9-10-6-12(24-2)4-5-14(10)25-3)11-7-13-15(18)21-17(19)22-16(13)20-8-11/h4-8H,9H2,1-3H3,(H4,18,19,20,21,22)
IUPAC Name
N6-[(2,5-dimethoxyphenyl)methyl]-N6-methylpyrido[2,3-d]pyrimidine-2,4,6-triamine
SMILES
COC1=CC(CN(C)C2=CC3=C(N=C2)N=C(N)N=C3N)=C(OC)C=C1
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Dihydrofolate reductaseProteinunknownNot AvailableHumanP00374 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.353 mg/mLALOGPS
logP2.14ALOGPS
logP1.66ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)16.08ChemAxon
pKa (Strongest Basic)4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area112.41 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity99.84 m3·mol-1ChemAxon
Polarizability36.41 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9961
Blood Brain Barrier+0.9415
Caco-2 permeable+0.6006
P-glycoprotein substrateSubstrate0.6539
P-glycoprotein inhibitor IInhibitor0.5262
P-glycoprotein inhibitor IIInhibitor0.7252
Renal organic cation transporterNon-inhibitor0.7005
CYP450 2C9 substrateNon-substrate0.8936
CYP450 2D6 substrateNon-substrate0.7982
CYP450 3A4 substrateSubstrate0.5878
CYP450 1A2 substrateInhibitor0.6037
CYP450 2C9 inhibitorNon-inhibitor0.5874
CYP450 2D6 inhibitorInhibitor0.6564
CYP450 2C19 inhibitorNon-inhibitor0.6781
CYP450 3A4 inhibitorNon-inhibitor0.6033
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5505
Ames testAMES toxic0.5985
CarcinogenicityNon-carcinogens0.8977
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5652 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6043
hERG inhibition (predictor II)Inhibitor0.7589
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as pyrido[2,3-d]pyrimidines. These are compounds containing the pyrido[2,3-d]pyrimidine ring system, which is a pyridopyrimidine isomer with three ring nitrogen atoms at the 1-, 3-, and 8- position.
KingdomChemical entities
Super ClassOrganic compounds
ClassOrganoheterocyclic compounds
Sub ClassPyridopyrimidines
Direct ParentPyrido[2,3-d]pyrimidines
Alternative ParentsDimethoxybenzenes / Anisoles / Phenylmethylamines / Phenoxy compounds / Benzylamines / Dialkylarylamines / Alkyl aryl ethers / Aminopyridines and derivatives / Aminopyrimidines and derivatives / Aralkylamines
SubstituentsDimethoxybenzene / P-dimethoxybenzene / Pyrido[2,3-d]pyrimidine / Anisole / Benzylamine / Phenol ether / Phenylmethylamine / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Phenoxy compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Nadph binding
Specific Function:
Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFRL1.
Gene Name:
DHFR
Uniprot ID:
P00374
Molecular Weight:
21452.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235 ]
Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:40